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Abstract Hydroxyrubin (OH-Dox), a neutral doxorubicin derivative that is only slightly cross-resistant to doxorubicin (Dox), can be actively 
pumped out of resistant K562 cells by P-glycoprotein (P-gp). This efllux is saturable and can be inhibited by verapamil. The Michaelis constant is 
equal to 2 f 0.5 PM. However, the efficiency of P-gp in pumping out the drugs is 2.5 times less for OH-Dox than for Dox. This shows that in order 
to be pumped out by P-gp a molecule does not necessarily have to have a basic center. The mean influx coefficient for the drug is 5 times higher 
for OH-Dox than for Dox. In conclusion, the degree of resistance of analogs is related not only to their ability to be recognized and transported 
by P-gp but also, and probably essentially, to their kinetics of uptake. Both parameters have to be taken into account in the rational design of new 
compounds capable of overcoming multidrug resistance. 
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1. rntroduction 
The multidrug resistance (MDR) cell phenotype reflects the 
capacity of some cell strains to display cross-resistance to cer- 
tain cytotoxic drugs (typically anthracyclines, vinca alkaloids, 
colchicine, etc.) [ 1,2]. It is now well established that the MDR 
phenotype is strongly correlated with the over-expression of 
P-gp, a 170-kDa membrane glycoprotein encoded by mdr class 
genes, that actively pumps drugs out of resistant cells. This 
effiux is energy dependent. 
It is now generally accepted that the uptake of drugs, such 
as anthracyclines, by cells occurs by passive diffusion of the 
neutral form of the drug [3-71. However, the mechanism ac- 
cording to which the drugs are removed from the cells is still 
unknown. It has been reported that (i) a wide variety of drugs 
recognized by P-gp are positively charged [8]; (ii) an ideal mod- 
ulator of P-gp would have at least two planar aromatic rings, 
a tertiary nitrogen that would be charged at physiological pH, 
and be relatively lipophilic [9]; and (iii) P-gp specifically pumps 
out the protonated form of daunorubicin [lo]. 
A better comprehension of the molecular requirements for 
drug-protein interactions is a necessary prerequisite to the ra- 
tional design of new compounds capable of overcoming MDR. 
To get some insight into that problem, we have studied the 
uptake and the efflux in reistant cells of a neutral molecule, 
OH-Dox, a synthetic analog of Dox in which the amine group 
of the sugar portion has been replaced by a hydroxyl group 
(Scheme 1) [l l-l 31. At neutral pH, about 96% of the amine 
group of Dox is protonated and the molecule carries a net 
positive charge of + 1 [6]. Substitution of a hydroxyl group for 
the amine group results in the loss of the positive charge. 
We present here data that clearly demonstrate (i) the exist- 
ence of P-gp-mediated efflux of the uncharged molecule (OH-Dox), 
and (ii) the fact that the kinetics of uptake must be taken into 
account when searching for new non-cross-resistant compounds. 
*Corresponding author. Fax: (33) (1) 48 38 77 77. 
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2. Materials and methods 
2.1. Cell culture and cytotoxicity assay 
Dox-sensitive and -resistant erythroleukemia K562 cells were rou- 
tinely cultured as described previously [6]. For the spectrofluorometric 
assays, in order to have cells in the exponential growth phase, culture 
was initiated at 5 x 10’ cells/ml, and cells were used 24 h later, when the 
culture had grown to about 8 x 10’ cells/ml. A ‘resistance factor’ was 
obtained by dividing the IC,, of resistant cells by the I&, of the corre- 
sponding sensitive cells. The resistance factors thus obtained were 30 
and 2.5 for Dox and OH-Dox, respectively. 
2.2. Drugs and chemicals 
Purified Dox (Scheme 1) was kindly provided by Laboratoire Roger 
Bellon (France), and OH-Dox was prepared according to the method 
of Horton et al. [1 11. Concentrations were determined by diluting stock 
solutions to approximately lo-’ M and using &480 = 11,500 M-’ .cn-‘. 
Stock solutions were prepared just before use. Verapamil was obtained 
from Sigma. All other reagents were of the highest quality available. 
Deionized double-distilled water was used throughout he experiments. 
Experiments were performed in HEPES Na+ buffer solutions contain- 
ing 20 mM HEPES buffer plus 132 mM NaCl, 3.5 mM KCl, 1 mM 
CaCl,, 0.5 mM MgCl,, pH 7.25, in either the presence or absence of 
5 mM glucose. 
Absorption spectra were recorded on a Cary 219 spectrophotometer 
and fluorescence spectra on a Jobin Yvon JY 3CS spectrofluorometer. 
2.3. Cellular drug accumulation 
The uptake of anthracycline in cells was followed by monitoring the 
decrease of the fluorescence signal at 590 nm @,, = 480 nm). This 
spectrofluorometric method has been previously described [6,14,15]. 
Using this method it is possible to accurately quantify the kinetics of 
uptake of the drug by the cells and the amount of anthracycline inter- 
calated between the base pairs in the nucleus in the steady state, since 
incubation of the cells with the drug proceeds without compromising 
cell viability. All experiments were conducted in 1 cm quartz cuvettes 
containing 2 ml of buffer at 37“C. 
2.4. Direct determination of the P-Gp-mediated efflux of OH-Dox and 
Dox 
Cells (1 x 106/ml were incubated for 30 min in the presence of 10 mM 
NaN, and in the absence of glucose in HEPES buffer. The incorpora- 
tion of OH-Dox in these energy-depleted resistant cells thus compared 
with that observed in sensitive cells. The addition, at steady state, of 
5 mM glucose gave rise to ATP synthesis via the glycolysis pathway and 
to an increase in the fluorescent signal due to the release of drug from 
the cells. The rate of the active eftlux was determined from the slope 
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of the tangent o the curve F = f (t) at the time point corresponding to 
the time of addition of glucose [16]. 
2.5. Cell nuclei preparation 
Cell nuclei were prepared according to the method of Mellon and 
Bhorjee [17]. 
3. Results 
3.1. Comparison of OH-Dox and Dox uptake by sensitive and 
resistant K562 cells 
Cells (2 x 106/ml) were incubated, at 37°C and pH 7.2, with 
various concentrations of OH-Dox ranging from 0.5 to 3 PM. 
In every case, steady state was reached within about 30 min. 
Fig. 1 shows a typical experiment dealing with 1 ,uM drug. As 
can be seen, the overall concentration of drug intercalated 
between the base pairs in the nucleus, C,,, was 0.12 f 0.02 PM 
for resistant cells and 0.35 f 0.03 ,uM for sensitive cells. After 
the addition of 0.05% Triton X-100, which permeabilized the 
membrane, yielding the equilibrium state [ 121, the overall con- 
centration of drug bound to the nuclei of both types of cells 
(C,) became the same and equal to 0.35 + 0.03 ,uM. 
The initial rate of uptake, V+, was determined from the slope 
of the tangent to the curves at t = 0 [6]. It was roughly propor- 
tional to the drug concentrations added to the cells at t = 0. V+ 
can be written in two ways [6]: either as (i) I’+ = k;n. [D,], 
where k, is the mean influx coefficient for the drug and depends 
on the extracellular pH value, [De] is the extracellular drug 
concentration, and n is the number of cells/ml, or as 
(ii) V+ = kz .n. [Di], where ky is the influx coefficient for the 
neutral form of the molecule and [Dz] is the extracellular con- 
centration of drug in the neutral form. The relationship be- 
tween the two coefficients is k, = kzl (1 + 10PKamPH). For OH- 
Dox, which can only be neutral, we have calculated that 
k, = k: = (2.0 k 0.5) x lo-” s-‘. 
Analogous experiments were performed with Dox. It is well 
known that its uptake by cells is very slow. In fact as the first 
pK, of deprotonation of Dox yielding the neutral species is 
equal to 8.4 [18], at pH 7.2, only 6% of the drug is in the neutral 
form and [D’J = 0.06 x [D,]. We have calculated that 
ky = (6.0 f 1.0) x 10-‘” s-l and that k, = (0.4 f 0.1) x lo-” s-l. 
f.$pJ&H.“. 
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Fig. 1. Uptake of hydroxydoxorubicin (OH-Dox) by drug-sensitive (S) 
and drug-resistant (R) K562 cells. Fluorescence intensity at 590 nm 
(il,, = 480 nm) was recorded as a function of time. Cells (4 x 106) were 
suspended in a cuvette filled with 2 ml buffer at pH, = 7.25 under 
vigorous stirring. At t = 0, 20 ,ILI of a 100 PM stock OH-Dox solution 
was added to the cells. vielding a C, = 1 uM OH-Dox solution. The 
fluorescence intensity ias then &. The slope of the tangent o the curve. 
F = f(t) at t = 0, was (dF/dt), = ,,, and the initial rate of uptake was 
V+ = (dF/dt), = O.(CT/F,). Once the steady state was reached, 
the fluorescence was F,, and the concentration of drug intercalated 
between the base pairs in the nucleus was C, = C,(F,-F,)IF,. The addi- 
tion of 0.05% Triton X-100 yielded the equilibrium state. The overall 
concentration C, of drug intercalated between the base pairs in the 
nucleus was then C, = C,.(F,-FJF,. 
3.2. Kinetics of the P-gp-mediated efJlux of OH-Dox and Dox 
Cells (2 x lo6 cells/ml) were incubated for 30 min, in the 
absence of glucose and in the presence of NaN,, with various 
concentrations of OH-Dox ranging from 0.5 to 7 PM. The 
accumulation of OH-Dox in these energy-deprived cells was the 
same as in sensitive cells. Fig. 2 shows a typical plot obtained 
with 1 ,uM drug. At the steady state, glucose was added, yield- 
ing ATP synthesis via the glycolysis pathway [16,19]. Under 
these conditions the active efllux of OH-Dox was observed. In 
every case, at steady state, and just before the addition of 
glucose, the free drug concentration in the cytosol, C; was 
equal to the free drug concentration in the extracellular me- 
dium. Active efflux, V,, was plotted as a function of C,‘, and a 
clear saturation of the active efllux was observed (Fig. 3). From 
these data we have estimated that the Michaelis constant, K,,,, 
was equal to about 2 + 0.5 ,uM (in the case of 4’-O-tetrahy- 
dropyranyl doxorubicin, we previously obtained K, -0.6 ,uM 
[16]). We checked that the active efflux of OH-Dox was com- 
pletely inhibited by 10 ,LM verapamil. 
To measure the active efIlux of Dox, 1 x lo6 cells/ml were 
incubated with 1 ,uM drug for 4 h in NaN,-containing buffer 
in the absence of glucose. However, even after such a long time, 
the overall concentration of drug bound to the nuclei was only 
0.28 ,uM. Under these conditions, in which the intra- and ex- 
tracellular pH are the same, the overall concentration of drug 
bound to the nuclei in the steady state is expected to be 0.5 ,uM, 
i.e. the same as in the equilibrium state [15]. It was not possible 
to increase the incubation time without cell perturbation, and 
glucose was added after 4 h despite the fact that the steady state 
was not reached. However, we took into account that the free 
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Fig. 2. Direct determination of the active kinetics of eftlux, V., of 
OH-Dox under the effect of P-au. Drug-resistant K562 cells (2 x 106/ml) 
were incubated with 1 PM OF?Dox in the presence of 10 mM N; and 
in the absence of glucose. Fluorescence intensity at 590 nm (A_ = 480 
nm) was recorded as a function of time. At steady state, the fluorescence 
intensity was F”i and the concentration ofdrug intercalated between the 
base pairs was equal to C,’ = C,(F,-$)IF,. At t = t,,,, 5 mM glucose 
was added, yielding the release of OH-Dox. The slope of the tangent 
to the curve was (dFldt),a, and the kinetics of release of OH-Dox was 
V, = (dF/dt) .(C,/F,). At the new steady state, the fluorescence 
intensity ,a?!“. The addition of 0.05% T&on X-100 yielded the equi- 
librium state. The fluorescence intensity was then FN. 
drug concentration, C’, was not the same as in the extracellular 
medium and so calculated it using the relationship that we have 
previously demonstrated, C,’ = C,. c;l/C,, where C, and C, 
stand for the overall drug concentration in the extracellular 
medium and bound to the nucleus in the equilibrium state, 
respectively [15,161. 
The active efflux, I’,, depends on the free drug concentration 
C’in the cytosol, and on the cell number, n. To compare the 
data obtained for both drugs, we calculated the parameter 
k, = VJCi’.n, hereafter named the active efflux coeffi- 
cient. k, was equal to 10 + 2 x lo-” s-r and 4 f 1 x 10-‘” s-i for 
Dox and OH-Dox, respectively. 
3.3. Interaction of OH-Dox and Dox with DNA and cell nuclei 
The quenching of OH-Dox and Dox fluorescence mission 
through DNA interaction was followed by adding increasing 
amounts of calf thymus DNA to a 1 PM antibiotic HEPES 
buffer solution at 37°C. FIFO was plotted as a function of the 
base pair concentration (data not shown). The titration mid- 
points of these curves were equal to 3 f 1 ,uM and 13 + 2 PM 
for Dox and OH-Dox, respectively. 
When 1 x lo6 nuclei/ml were incubated with antibiotics of 
1 ,uM concentration, the overall concentration of drug interca- 
lated between the base pairs in the nuclei was 0.18 f 0.02 and 
0.5 + 0.03 ,uM, respectively. 
4. Discussion 
4.1. OH-Dox is 2.5 times less effective than Dox in inhibiting the 
growth of sensitive cells 
This can be perfectly correlated with the amount of drug 
present in the cell nuclei at steady state, with the amount of 
drug that binds isolated cell nuclei, and with the affinity of the 
two drugs for DNA. Thus, when 1 x lo6 sensitive cells/ml are 
incubated with 1 PM drug, the overall concentration of drug 
bound to the nuclei is -3-fold higher for Dox than for OH-Dox. 
The same ratio is obtained when drugs are incubated with cell 
nuclei. Moreover, the affinity for DNA is -4-fold higher for Dox 
than for OH-Dox. This last point corroborates the recent data 
of Chaires et al. [20]. This clearly shows that the cytotoxicity 
of an anthracycline is mainly governed by the amount of drug 
present inside the cell nuclei, which is itself determined by the 
drug’s affinity for DNA. 
4.2. OH-Dox is 5 times more effective than Dox in inhibiting the 
growth of resistant cells 
This indicates that the amount of drug bound to the cell 
nuclei is higher in the case of OH-Dox than in the case of Dox. 
One interpretation is that OH-Dox is not transported by P-gp. 
Our data clearly show that this neutral molecule is pumped out 
by P-gp, albeit less efficiently than Dox; that the active efllux 
of OH-Dox is saturable, and that it can be inhibited by vera- 
pamil. The efficiency of P-gp in pumping out the drugs is 2.5 
times less for OH-Dox than for Dox. Results indicate that, to 
be pumped out by P-gp, a molecule does not necessarily have 
to have a basic center. 
The second parameter that has to be taken into account is 
the kinetics of uptake of the drugs by the cells. The mean influx 
coefficient for the drug is 5 times higher for OH-Dox than for 
Dox. To reach a high intracellular drug concentration, the 
influx coefficient k, should be the highest and the active efflux 
coefficient k, should be the lowest. These two conditions can 
be taken into account simultaneously by the ratio k,lk+, which 
should be as low as possible. This ratio is equal to 25 and 2 for 
Dox and OH-Dox, respectively, and corresponds well with the 
degree of resistance (30 and 2.5 for Dox and OH-Dox, respec- 
tively). 
In conclusion, we can say that the degree of resistance of 
anthracyclines is related not only to their ability to be recog- 
nized and transported by P-gp but also to their kinetics of 
uptake. Both parameters must be taken into account in the 
rational design of new compounds capable of overcoming 
MDR. 
0 i 
C’i PM 
Fig. 3. Variation of kinetics of P-gp-mediated eftlux of OH-Dox as a 
function of C;: the cytosol free drug concentration. Resistant cells 
(2 x 106/ml) were incubated in the presence of various concentrations 
of OH-Dox ranging from 0.5 to 7 PM. V, and C,' were determined as 
described in section 2. 
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